ASP8062 + Placebo ASP8062 + buprenorphine/naloxone

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Opioid Use Disorder

Conditions

Opioid Use Disorder

Trial Timeline

Jun 29, 2020 โ†’ Nov 25, 2020

About ASP8062 + Placebo ASP8062 + buprenorphine/naloxone

ASP8062 + Placebo ASP8062 + buprenorphine/naloxone is a phase 1 stage product being developed by Astellas Pharma for Opioid Use Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04447287. Target conditions include Opioid Use Disorder.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT05062577Phase 2Withdrawn
NCT04447287Phase 1Completed

Competing Products

20 competing products in Opioid Use Disorder

See all competitors
ProductCompanyStageHype Score
SUBLOCADEIndivior PLCPhase 3
72
SUBLOCADEIndivior PLCPhase 3
72
ASP8082 + morphine + PlaceboAstellas PharmaPhase 1
33
ASP8062 + Placebo ASP8062 + buprenorphine/naloxoneAstellas PharmaPhase 2
52
Naldemedine + PlaceboShionogiPhase 3
77
Naldemedine + PlaceboShionogiApproved
85
NaldemedineShionogiPhase 1/2
41
Naldemedine + PlaceboShionogiPhase 3
77
Placebo + NaldemedineShionogiPhase 2
52
Naldemedine + PlaceboShionogiPhase 3
77
Naldemedine + PlaceboShionogiPhase 2
52
NaloxegolKyowa KirinPre-clinical
23
naloxegol + non-PAMORA laxativeKyowa KirinPre-clinical
23
NaloxegolKyowa KirinPre-clinical
23
NaloxegolKyowa KirinPre-clinical
23
Brenipatide + Placebo + BuprenorphineEli LillyPhase 2
52
NKTR-118 + NKTR-118 + PlaceboAstraZenecaPhase 3
77
Naloxegol + NaloxegolAstraZenecaPhase 1
33
NKTR-118 + Usual careAstraZenecaPhase 3
77
Polyethylene Glycol 3350 + MovantikAstraZenecaApproved
85